News Column

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

September 10, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced that management is scheduled to present a company overview at the following investor conferences in September. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter (see also Sarepta Therapeutics, Inc.).

Baird 2014 Health Care Conference in New York, NY on Thursday, September 4, 2014, at 12:50 p.m. ET.

Morgan Stanley Global Healthcare Conference 2014 in New York, NY on Wednesday, September 10, 2014, at 2:40 p.m. ET.

The presentations will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be achieved under the events and presentations section following the presentation for 90 days. About Sarepta Therapeutics Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

Keywords for this news article include: Sarepta Therapeutics, Sarepta Therapeutics Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters